Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody.
On 22 April 2008, Roche Registration Limited chose to voluntarily withdraw the marketing authorization for their product Zenapax (daclizumab), as indicated for the prophylaxis of acute organ rejection in de novo allogeneic renal transplantation and used concomitantly with an immunosuppressive regimen like cyclosporine and corticosteroids in patients who are not hight immunized, for commercial reasons and confirmed that this decision was not related to any safety concerns associated with the use of Zenapax (daclizumab) L1744. Regardless of the withdrawal of Zenapax, Biogen and Abbvie's Zinbryta (daclizumab), as indicated for the treatment of adult patients with relapsing forms of multiple sclerosis, was approved for use by the FDA in 2016 L1746.
Despite being approved for use, Zinbryta (daclizumab)'s complex pre-existing safety profile consisting of its restricted availability through a Risk Evaluation and Mitigation Strategy program L1738 and its black box warning for possible hepatic injury, autoimmune hepatitis, and other immune mediated disorders L1738 meant its therapeutic usage, adverse effects, and prescribing information was subject to continuous monitoring and updating.
Although Zinbryta (daclizumab) was available for patients as needed until 30 April 2018, Biogen and Abbvie announced a voluntary withdrawal of their product Zinbryta (daclizumab) from the global market on 2 March 2018 L1738. This withdrawal was concurrent to the European Medicines Agency announcement of a recall owing to 12 worldwide reports of serious inflammatory brain disorders associated with the use of Zinbryta (daclizumab) L1738.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Daclizumab. |
| Etanercept | The risk or severity of adverse effects can be increased when Etanercept is combined with Daclizumab. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Daclizumab. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Daclizumab. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Daclizumab. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Daclizumab. |
| Anakinra | The risk or severity of adverse effects can be increased when Anakinra is combined with Daclizumab. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Daclizumab. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Daclizumab. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Daclizumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Daclizumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Daclizumab. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Daclizumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Daclizumab. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Daclizumab. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Daclizumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Daclizumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Daclizumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Daclizumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Daclizumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Daclizumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Daclizumab. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Daclizumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Daclizumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Daclizumab. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Daclizumab. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Daclizumab is combined with Phenylalanine. |
| Flunisolide | The risk or severity of adverse effects can be increased when Daclizumab is combined with Flunisolide. |
| Bortezomib | The risk or severity of adverse effects can be increased when Daclizumab is combined with Bortezomib. |
| Cladribine | Daclizumab may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Daclizumab is combined with Carmustine. |
| Amsacrine | The risk or severity of adverse effects can be increased when Daclizumab is combined with Amsacrine. |
| Bleomycin | The risk or severity of adverse effects can be increased when Daclizumab is combined with Bleomycin. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Daclizumab is combined with Chlorambucil. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Daclizumab is combined with Raltitrexed. |
| Mitomycin | The risk or severity of adverse effects can be increased when Daclizumab is combined with Mitomycin. |
| Bexarotene | The risk or severity of adverse effects can be increased when Daclizumab is combined with Bexarotene. |
| Vindesine | The risk or severity of adverse effects can be increased when Daclizumab is combined with Vindesine. |
| Floxuridine | The risk or severity of adverse effects can be increased when Daclizumab is combined with Floxuridine. |
| Indomethacin | The risk or severity of adverse effects can be increased when Daclizumab is combined with Indomethacin. |
| Tioguanine | The risk or severity of adverse effects can be increased when Daclizumab is combined with Tioguanine. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Daclizumab is combined with Vinorelbine. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Daclizumab is combined with Dexrazoxane. |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Daclizumab is combined with Beclomethasone dipropionate. |
| Sorafenib | The risk or severity of adverse effects can be increased when Daclizumab is combined with Sorafenib. |
| Streptozocin | The risk or severity of adverse effects can be increased when Daclizumab is combined with Streptozocin. |
| Trifluridine | The risk or severity of adverse effects can be increased when Daclizumab is combined with Trifluridine. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Daclizumab is combined with Gemcitabine. |
| Betamethasone | The risk or severity of adverse effects can be increased when Daclizumab is combined with Betamethasone. |
| Teniposide | The risk or severity of adverse effects can be increased when Daclizumab is combined with Teniposide. |
| Epirubicin | The risk or severity of adverse effects can be increased when Daclizumab is combined with Epirubicin. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Daclizumab is combined with Chloramphenicol. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Daclizumab is combined with Lenalidomide. |
| Altretamine | The risk or severity of adverse effects can be increased when Daclizumab is combined with Altretamine. |
| Zidovudine | The risk or severity of adverse effects can be increased when Daclizumab is combined with Zidovudine. |
| Cisplatin | The risk or severity of adverse effects can be increased when Daclizumab is combined with Cisplatin. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Daclizumab is combined with Oxaliplatin. |
| Cyclophosphamide | The risk or severity of adverse effects can be increased when Daclizumab is combined with Cyclophosphamide. |
| Vincristine | The risk or severity of adverse effects can be increased when Daclizumab is combined with Vincristine. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluorouracil. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Daclizumab is combined with Propylthiouracil. |
| Pentostatin | The risk or severity of adverse effects can be increased when Daclizumab is combined with Pentostatin. |
| Methotrexate | The risk or severity of adverse effects can be increased when Daclizumab is combined with Methotrexate. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Daclizumab is combined with Carbamazepine. |
| Vinblastine | The risk or severity of adverse effects can be increased when Daclizumab is combined with Vinblastine. |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluticasone propionate. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluocinolone acetonide. |
| Linezolid | The risk or severity of adverse effects can be increased when Daclizumab is combined with Linezolid. |
| Imatinib | The risk or severity of adverse effects can be increased when Daclizumab is combined with Imatinib. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Daclizumab is combined with Triamcinolone. |
| Clofarabine | The risk or severity of adverse effects can be increased when Daclizumab is combined with Clofarabine. |
| Prednisone | The risk or severity of adverse effects can be increased when Daclizumab is combined with Prednisone. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Daclizumab is combined with Pemetrexed. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Daclizumab is combined with Fludrocortisone. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Daclizumab is combined with Mycophenolate mofetil. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Daclizumab is combined with Daunorubicin. |
| Irinotecan | The risk or severity of adverse effects can be increased when Daclizumab is combined with Irinotecan. |
| Methimazole | The risk or severity of adverse effects can be increased when Daclizumab is combined with Methimazole. |
| Etoposide | The risk or severity of adverse effects can be increased when Daclizumab is combined with Etoposide. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Daclizumab is combined with Sulfasalazine. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Daclizumab is combined with Dacarbazine. |
| Temozolomide | The risk or severity of adverse effects can be increased when Daclizumab is combined with Temozolomide. |
| Penicillamine | The risk or severity of adverse effects can be increased when Daclizumab is combined with Penicillamine. |
| Prednisolone | The risk or severity of adverse effects can be increased when Daclizumab is combined with Prednisolone. |
| Sirolimus | The risk or severity of adverse effects can be increased when Daclizumab is combined with Sirolimus. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Daclizumab is combined with Mechlorethamine. |
| Azacitidine | The risk or severity of adverse effects can be increased when Daclizumab is combined with Azacitidine. |
| Carboplatin | The risk or severity of adverse effects can be increased when Daclizumab is combined with Carboplatin. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Daclizumab is combined with Methylprednisolone. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Daclizumab is combined with Dactinomycin. |
| Cytarabine | The risk or severity of adverse effects can be increased when Daclizumab is combined with Cytarabine. |
| Azathioprine | The risk or severity of adverse effects can be increased when Daclizumab is combined with Azathioprine. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Daclizumab is combined with Doxorubicin. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Daclizumab is combined with Hydroxyurea. |
| Busulfan | The risk or severity of adverse effects can be increased when Daclizumab is combined with Busulfan. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Daclizumab is combined with Mycophenolic acid. |
| Topotecan | The risk or severity of adverse effects can be increased when Daclizumab is combined with Topotecan. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Daclizumab is combined with Mercaptopurine. |
| Thalidomide | The risk or severity of adverse effects can be increased when Daclizumab is combined with Thalidomide. |
| Melphalan | The risk or severity of adverse effects can be increased when Daclizumab is combined with Melphalan. |